NCT06730477View on ClinicalTrials.gov

Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma

Enrolling by invitationOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
Lung AdenocarcinomaEGFR Activating Mutation
Interventions
OTHER

observational study

Efficacy of targeted therapy combined with or without chemotherapy as first-line therapy in patients with EGFR-mutated lung adenocarcinoma.

Trial Locations (1)

430022

Union hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

Yichang Central People's Hospital

OTHER

collaborator

Suizhou Hospital, Hubei University of Medicine

UNKNOWN

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER